Diagnostic and prognostic application of Raman spectroscopy in carcinoma cervix: A biomolecular approach

Spectrochim Acta A Mol Biomol Spectrosc. 2021 Apr 5:250:119356. doi: 10.1016/j.saa.2020.119356. Epub 2020 Dec 22.

Abstract

Blood serum samples from 63 cervical cancer patients and 30 controls were collected at three different phases of the treatment (i.e. before, during, and at follow up). The spectra of serum samples from control as well as patients were classified into different groups using principal component analysis (PCA) and linear discriminant analysis (LDA) based on different phases of treatment using R software. The spectra of blood serum samples have shown the distinct changes and differences compared with each other in the profile of various biochemical parameters. The sensitivity (92.5%) and specificity (85%) were observed maximum between control and cervical cancer patients (before treatment). Between different phases of treatment, the sensitivity and specificity were less but, all accuracies of detection and classification reached above 50%. This method can be considered as a screening method for detection and treatment monitoring.

Keywords: Biomolecules; Carcinoma of the cervix; Concurrent chemoradiotherapy; Raman spectroscopy.

MeSH terms

  • Discriminant Analysis
  • Female
  • Humans
  • Principal Component Analysis
  • Prognosis
  • Spectrum Analysis, Raman*
  • Uterine Cervical Neoplasms* / diagnosis